E2F-3 Antibody (TFE36): sc-56666

E2F-3 Antibody (TFE36) is a mouse monoclonal IgG2b antibody that detects E2F-3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). E2F-3 plays a crucial role in regulating the cell cycle, particularly in the transition from the G1 phase to the S phase, where DNA replication occurs. This regulation is vital for proper cell proliferation and differentiation, as dysregulation of E2F-3 can lead to uncontrolled cell growth and is often implicated in various cancers. E2F-3 is primarily located in the nucleus, where E2F-3 binds to specific DNA sequences to activate the transcription of genes necessary for cell cycle progression. Understanding E2F-3 localization is important because nuclear presence is essential for function as a transcription factor, and any aberrations in localization can disrupt normal cell cycle regulation. E2F-3 interacts with other members of the E2F family and forms heterodimers with the DP-1 protein, which enhances transcriptional activity, further emphasizing the importance of structural and functional integrity in cellular processes. Anti-E2F-3 antibody (TFE36) is an invaluable tool for researchers studying cell cycle dynamics and the molecular mechanisms underlying tumorigenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

E2F-3 Antibody (TFE36) References:

1. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3.  |  Han, R., et al. 2019. Cancer Manag Res. 11: 2963-2976. PMID: 31114344
2. MicroRNA-432 Suppresses Invasion and Migration via E2F3 in Nasopharyngeal Carcinoma.  |  Wang, T., et al. 2019. Onco Targets Ther. 12: 11271-11280. PMID: 31908492
3. Critical functions of microRNA-30a-5p-E2F3 in cardiomyocyte apoptosis induced by hypoxia/reoxygenation.  |  Lv, XB., et al. 2021. Kaohsiung J Med Sci. 37: 92-100. PMID: 33058540
4. Expression and prognostic value of E2F3 transcription factor in non-small cell lung cancer.  |  Wu, L., et al. 2021. Oncol Lett. 21: 411. PMID: 33841572
5. E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer.  |  Jusino, S., et al. 2021. Exp Biol Med (Maywood). 246: 2057-2071. PMID: 34365840
6. Epstein-Barr Virus miR-BART1-3p Regulates the miR-17-92 Cluster by Targeting E2F3.  |  Park, MC., et al. 2021. Int J Mol Sci. 22: PMID: 34681596
7. eIF4A3-induced circWAC promotes breast cancer progression through mediating miR-599/E2F3 axis.  |  Huang, WH., et al. 2022. Kaohsiung J Med Sci. 38: 321-335. PMID: 34989110
8. rtcisE2F promotes the self-renewal and metastasis of liver tumor-initiating cells via N6-methyladenosine-dependent E2F3/E2F6 mRNA stability.  |  Chen, Z., et al. 2022. Sci China Life Sci. 65: 1840-1854. PMID: 35266112
9. E2F3 renders an immunosuppressive tumor microenvironment in nasopharyngeal carcinoma: Involvements of the transcription activation of PRC1 and BIRC5.  |  Wang, Q., et al. 2023. Immun Inflamm Dis. 11: e987. PMID: 37647439
10. E2F3/CDCA2 reduces radiosensitivity in gastric adenocarcinoma by activating PI3K/AKT pathway.  |  Gao, J., et al. 2023. Br J Radiol. 96: 20230477. PMID: 37750838

The preferred E2F-3 antibody is E2F-3 Antibody (PG30): sc-56665.